Andexanet Alfa for Acute Major Bleeding Associated with Factor Xa Inhibitors.

@article{Connolly2016AndexanetAF,
  title={Andexanet Alfa for Acute Major Bleeding Associated with Factor Xa Inhibitors.},
  author={Stuart J. Connolly and Truman John Milling and John W. Eikelboom and C Michael Gibson and John T. Curnutte and Alex Gold and Michele D Bronson and Genmin Lu and Pamela B Conley and Peter B. Verhamme and Jeannot Schmidt and Saskia Middeldorp and Alexander A. Cohen and Jan Beyer-Westendorf and Pierre Albalad{\'e}jo and Jos{\'e} Lu{\'i}s L{\'o}pez-Send{\'o}n and Shelly Goodman and Janet M. Leeds and Brian L. Wiens and Deborah M. Siegal and Elena Zotova and Brandi Meeks and Juliet Nakamya and Woo-Hyun Lim and Mark Andrew Crowther},
  journal={The New England journal of medicine},
  year={2016},
  volume={375 12},
  pages={
          1131-41
        }
}
BACKGROUND Andexanet alfa (andexanet) is a recombinant modified human factor Xa decoy protein that has been shown to reverse the inhibition of factor Xa in healthy volunteers. METHODS In this multicenter, prospective, open-label, single-group study, we evaluated 67 patients who had acute major bleeding within 18 hours after the administration of a factor Xa inhibitor. The patients all received a bolus of andexanet followed by a 2-hour infusion of the drug. Patients were evaluated for changes… CONTINUE READING

Citations

Publications citing this paper.
Showing 1-10 of 136 extracted citations

References

Publications referenced by this paper.
Showing 1-10 of 12 references

Efficacy and safety of a 4-factor prothrombin complex concentrate in patients on vitamin K antagonists presenting with major bleeding: a randomized, plasmacontrolled, phase IIIb study

  • R Sarode, TJ JrMilling, MA Refaai
  • Circulation
  • 2013

Similar Papers

Loading similar papers…